Oncolytics Biotech Inc. (ONCY)

[onco_investor]

Positive Interim Trial Results Presented in Amsterdam

http://finance.yahoo.com/news/Oncolytics-Biotech-Inc-prnews-300044770.html?x=0&.v=33

Selected for a Mini Oral Presentation from 1500 abstracts submitted and 400 accepted at the World Lung Cancer Conference. Detailed patient by patient results included showing EGFR/KRAS status and TTP.

CALGARY, July 6, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC.to - News) ("Oncolytics") today announced that a presentation covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours was made today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. The conference is being held in Amsterdam, the Netherlands from July 3rd - 7th 2011.

The presentation, entitled "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors", was given by Dr. Miguel Villalona-Calero, principal investigator for the study, and indicated that 22 patients had received Reovirus (REOLYSIN) (3 x 1010 TCID50) intravenously daily on days one to five, in combination with carboplatin and paclitaxel. Initial doses used were carboplatin AUC 6 on day one, and palitaxel 200 mg/m2, on day one of each 21-day cycle. Due to exacerbation of prior gastrointestinal conditions and febrile neutropenia (one each) in the first two patients, doses were reduced to paclitaxel 175 mg/m2 and carboplatin AUC 5.

To date the study has enrolled patients with Adenocarcinoma (15), Squamous Cell Carcinoma (three), Bronchioloalveolar Carcinoma (one), and not otherwise specified non-small cell lung cancer (three). Molecular tumor demographics included: nine Kras mutant, three EGFR mutant, 16 EGFR amplified. Response evaluation to date in 21 patients showed six partial responses (PR) (28.6%), 13 stable disease (SD) (61.9%), two progressive disease (PD) (9.5%). This translates into a clinical benefit rate (complete response (CR)+PR+SD) of 90.5% and a response rate (CR+PR) of 28.6%. The investigators noted that the clinical benefit noted so far is encouraging and that a follow up randomized clinical trial appears warranted.

"The patient response and clinical benefit rates observed in this trial are very encouraging. We will decide which lung cancer indication will proceed into a randomized clinical study based on this data and the data we expect from our ongoing Phase II trial in squamous cell carcinoma lung cancer," said Dr. Brad Thompson, President and CEO of Oncolytics.

The full presentation is available on the Company's website at www.oncolyticsbiotech.com.

Conference Call Details

Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Wednesday, July 6th, 2011 at 6:30 a.m. MT (8:30 a.m. ET) to discuss in more depth the presentation covering the Phase II NSCLC data. To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3563560 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through July 13th, 2011. To access the telephone replay, dial 1-416-849-0833 or 1-800-642-1687 and enter reservation number 78454074 followed by the number sign.




Link to the slide show at
http://media.integratir.com/T.ONC/ppt/Dr%20%20V%20Reo%20IASLC.pdf

Interim Conclusions based on 21 evaluatable patients:
- Patient selection based on molecular profile for first line therapy in NSCLC is feasible.

- Reovirus can be administered safety in combination with C/P

- Clinical benefit observed so far is encouraging (90+% in Stage 4 patients)

- Historical controls are not informative on the effect of chemotherapy in Kras activated NSCLC

- A randomized trial to differentiate the contribution of the reovirus to the chemotherapy appears warranted.